about
Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectivesFBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseResponse of histiocytoses to imatinib mesylate: fire to ashesBRAF mutations in advanced cancers: clinical characteristics and outcomesA phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabPhase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerPhase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsAntiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerClinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester diseaseCharacteristics and survival of patients with advanced cancer and p53 mutations.PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitorsMABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsMutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.A framework for genomic biomarker actionability and its use in clinical decision makingClinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience
P50
Q27006707-2389492E-0112-4A93-A48B-B0A559EA0EB5Q27852932-C8C989DD-CF7A-4695-B314-FF132BB3D90DQ27853020-DD2D711B-65B0-4D6C-9FAC-7F5A87F679D2Q27853224-71A3E9A3-3672-4273-AA46-456BCCDB9D8FQ28240576-F56253AF-6899-41CF-88CE-EDA73B15B19BQ28291341-0EF3A966-164C-46F8-81D1-89CE1D17CB28Q28743591-20C826C8-B3F8-4952-B78F-7FEB9B4047E7Q33373488-7046521D-9EC9-4AC4-B6A3-E5BD15660C12Q33397006-4E85FC8F-6692-42A0-97DE-0F0063093473Q33408279-78DC8C80-069F-4BB3-B49B-23FE43A82D84Q33410022-58598AF3-0675-49F8-B1EB-51ED14442850Q33413618-484E627C-1449-43FE-AE43-283EB0459012Q33418562-0AEE1BFB-889A-4B32-96F9-C14FC4F24DDCQ33422258-6AAFADCD-B83D-48DF-A9F5-1C44CFA9C1C4Q33422964-F1591B1D-FC06-4602-9EF8-3185E0E2D3B9Q33424270-CDA72254-A20F-4DD0-A7CC-03D3CF1142FFQ33431248-9CB57508-3F3E-4FB5-AE2C-748D1F95B64BQ33435113-0E532F2A-836B-496E-B212-D749729C5DFDQ33439312-0B2B1BF4-6B48-4320-80F1-F159CDC55E77Q33441143-04F41ADF-7888-4883-A586-8F0BF38CA3F4Q33572971-7607B633-D406-40B5-8305-8BCE43963909Q33688421-04D5BBC8-5BD8-4460-B30D-1A39E589DB74Q33756991-C3A11F69-F1AD-4F4B-AC04-93E4F79DFEC7Q33779691-B8808B80-4D25-45C1-8032-FAD1D6DFDB04Q33889152-398886E8-57FF-4124-900A-A9455F3B8EC5Q33917547-812C6330-DC2E-4571-BDE5-685D9A8F6E15Q33917551-CC35AA9E-EC50-4797-A5DE-ECF6D11B44C6Q33976971-8CFD6EF8-2451-460B-A8D7-75B5C13E792AQ33977102-0AAB0C5A-25E2-4D04-AD34-5E16CF12133FQ33987852-01B8EB72-47C1-4622-91F1-003C6FDFA044Q34107482-ED656551-619A-4F8B-A897-2CF7D724B2C2Q34153696-A609B642-F119-45F6-9AB6-D188BF80AA9AQ34295425-7AF0E929-BBB9-4D2B-A44F-6CBA2F1A8C7DQ34415973-DDE87AE3-0848-416C-AD6D-B125849D02D1Q34619163-BAC79860-AAC7-4FD8-888E-240A32D7CBE8Q34646376-7986C411-4A5E-4462-B983-B7A7D6688443Q34764681-127C798D-B9F7-47AA-8035-0839687D8804Q34769343-178EC6D1-0DFD-4447-8D23-836C9E283178Q34781122-72FD295E-CFC4-4890-8653-4E9D8188D7D4Q34781347-9E8FF5F7-C186-48F7-9A63-BCDE2C2645BE
P50
name
Filip Janku
@en
Filip Janku
@nl
type
label
Filip Janku
@en
Filip Janku
@nl
prefLabel
Filip Janku
@en
Filip Janku
@nl